You can buy Daconib at the lowest price in the online pharmacy Nextgen.ooo . Dacomitinib is a drug used to treat non-small cell lung cancer with a deletion of EGFR exon 19 and a L858R replacement of exon 21.
Dacomitinib is an orally administered, highly selective quinazolone component of the second-generation tyrosine kinase inhibitors, which are characterized by irreversible binding at the ATP domain of the kinase domains of the epidermal growth factor receptor family.
Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. Some data in the literature suggest therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further studies are needed.
Dacomitinib is indicated as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations confirmed by an FDA-approved test.
 
Lung cancer is the leading cause of cancer death, and NSCLC accounts for 85% of lung cancer cases. For NSCLC cases, approximately 75% of patients are diagnosed at a late stage with metastatic and advanced disease, resulting in a survival rate of 5%. The presence of an EGFR mutation accounts for more than 60% of NSCLC cases, and EGFR overexpression is associated with frequent lymph node metastasis and poor chemosensitivity.